Goldline Pharmaceutical IPO Allotment Status

Listed RegistrarBigshare Services Pvt. Ltd. Allotment15 May 2026 Listed at₹59.75 +38.95%

Check Goldline Pharmaceutical Allotment Status by PAN

Enter the PAN you applied with — the result comes straight from Bigshare Services Pvt. Ltd..

10 characters: 5 letters, 4 digits, 1 letter

Not getting a result here? You can also check Goldline Pharmaceutical allotment directly on the Bigshare Services portal →

Check every IPO in one tap

  1. 1Sign in with Google — no password, free
  2. 2Save your PAN — and your family's, up to 10
  3. 3Check any IPO — all saved PANs at once
Continue with Google

🔒 PANs are shown masked and can be removed anytime.

Goldline Pharmaceutical IPO — Allotment & Listing Timeline

  1. IPO Open 12 May 2026
  2. IPO Close 14 May 2026
  3. Basis of Allotment 15 May 2026
  4. Refund Initiation 18 May 2026
  5. Listing Date 19 May 2026
Issue Price₹41–43
Issue Size₹12.00 Cr
IPO TypeSME
Listing AtBSE
RegistrarBigshare Services Pvt. Ltd.
Listing Price₹59.75
Listing Gain+38.95%

Goldline Pharmaceutical IPO — Subscription & Allotment Odds

Based on the latest subscription figures for Goldline Pharmaceutical IPO (overall 840.57x subscribed). The more a category is oversubscribed, the lower each applicant's chance of allotment.

Retail 0.13% (880.68x)
Low chance
S-HNI 0.06% (1,662.35x)
Low chance
B-HNI 0.30% (1,662.35x)
Low chance

In the Retail category, about 1 in 1,000 applicants would get an allotment in Goldline Pharmaceutical IPO. Winners are picked by draw of lots and each gets 6,000 shares (2 lots), so applying for more than the minimum does not improve retail odds.

How Many Goldline Pharmaceutical Retail Applicants Get Shares

Retail shares reserved9,00,000
Minimum application6,000 shares · ₹2,58,000
Retail winners (max)150
Retail applications (est.)~1,15,879

Goldline Pharmaceutical set aside 9,00,000 shares for retail (individual) investors. Each successful applicant receives 6,000 shares (2 lots), so the retail quota can serve at most 150 applicants. With retail subscribed 880.68x, that points to roughly 1,15,879 retail applications competing for those allotments.

Estimate from the prospectus reservation and the final subscription; the registrar's Basis of Allotment has the exact count.

Goldline Pharmaceutical IPO Subscription, Day by Day

Times subscribed at the close of each bidding day.

DayRetailNII QIB Total
Day 1 34.07x 24.46x 1.31x 22.35x
Day 2 139.51x 146.48x 1.31x 100.21x
Day 3 880.68x 1,662.35x 180.22x 840.57x

Retail demand grew from 34.07x on day 1 to 880.68x by day 3 — 25.8x over the bidding window.

What Goldline Pharmaceutical Allottees Made on Listing Day

Issue price₹43.00
Listing price₹59.75
Per minimum application+₹1,00,500
Last GMP before listing₹15

Goldline Pharmaceutical listed at ₹59.75 (+38.95% on the issue price). An applicant allotted 6,000 shares (2 lots) was up about ₹1,00,500 at the listing price, before charges. The last grey market premium we recorded (₹15 on 18 May) pointed to about ₹58; the actual listing was ₹2 higher.

Checking Goldline Pharmaceutical Allotment

Enter the PAN you applied with in the box above; the check goes to Bigshare Services Pvt. Ltd., the registrar for Goldline Pharmaceutical IPO, which finalised the allotment on 15 May 2026.

How the draw of lots works is the same for every issue — see IPO Allotment Process Explained. See all recent IPO allotment results. Last updated: 15 May 2026, 07:38 pm IST.

Goldline Pharmaceutical Allotment FAQs

The registrar for Goldline Pharmaceutical IPO is Bigshare Services Pvt. Ltd., which finalised the allotment on 15 May 2026.

The Goldline Pharmaceutical IPO allotment date was 15 May 2026; the issue closed on 14 May 2026.

The amount blocked through your ASBA / UPI mandate is released within 1-2 working days of the 15 May 2026 allotment; the refund date for Goldline Pharmaceutical was 18 May 2026. With retail subscribed 880.68x, roughly 100% of retail applicants were expected to miss out.

Goldline Pharmaceutical lists on 19 May 2026; allotted shares are credited one working day earlier, on or just before 18 May 2026.

Goldline Pharmaceutical was subscribed 840.57x overall. Oversubscribed categories are allotted by draw of lots, each winner getting the minimum application, which in retail is 6,000 shares (2 lots). Estimated odds: Retail 880.68x, about 0.1%; S-HNI 1,662.35x, about 0.1%; B-HNI 1,662.35x, about 0.3%. QIB is allotted proportionately, not by lottery.
GMPUpdate